Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cloxacillin→

Cloxacillin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
61-72-3
Molecular formula
C19H18ClN3O5S
Molecular weight
435.9 g/mol
Drug class
Penicillinase-resistant isoxazolyl penicillinbeta-lactam antibacterial
Mechanism of action
Binds penicillin-binding proteins and inhibits bacterial peptidoglycan cell-wall synthesis. Its isoxazolyl side chain confers resistance to many staphylococcal beta-lactamases, providing activity against susceptible penicillinase-producing Staphylococcus aureus.
Indications / reported uses
  • Treatment of infections caused by susceptible penicillinase-producing staphylococci, including skin and soft-tissue infections, cellulitis, wound infections, osteomyelitis and selected bloodstream infections; use should be guided by susceptibility and local antimicrobial guidance

Sources: NLM MeSH — Cloxacillin · NHS — Flucloxacillin and staphylococcal infection guidance (class pharmacology) · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Penicillinase-resistant isoxazolyl penicillin; beta-lactam antibacterial

Mechanism of action

Binds penicillin-binding proteins and inhibits bacterial peptidoglycan cell-wall synthesis. Its isoxazolyl side chain confers resistance to many staphylococcal beta-lactamases, providing activity against susceptible penicillinase-producing Staphylococcus aureus.

General use cases

  • Treatment of infections caused by susceptible penicillinase-producing staphylococci, including skin and soft-tissue infections, cellulitis, wound infections, osteomyelitis and selected bloodstream infections; use should be guided by susceptibility and local antimicrobial guidance

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Cloxacillin Environmental Risk Assessment (ERA) (the Cloxacillin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.